M Ikeda1, S Okada, K Tokuuye, H Ueno, T Okusaka. 1. Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan.
Abstract
BACKGROUND: The combination of radiation therapy and chemotherapy (chemoradiotherapy [CRT]) has been accepted as standard therapy for patients with locally advanced pancreatic carcinoma (PC). This study investigated prognostic factors in patients with locally advanced PC receiving CRT. METHODS: Fifty-five consecutive patients with locally advanced PC, who received concurrent radiotherapy (50.4 grays) and chemotherapy using 5-fluorouracil or cisplatin, were analyzed retrospectively to investigate prognostic factors. RESULTS: Median survival time and overall survival rates at 1 and 2 years were 301 days, 35.1% and 2.4%, respectively. By multivariate analysis using the Cox proportional hazards model, performance status of 0-1 (P < 0.01), absence of regional lymph node swelling (P < 0.01), and serum CA 19-9 level of less than 1000 (P = 0.02) were independent favorable prognostic factors. A prognostic index based on the coefficients of those prognostic factors was used to classify patients into three groups with good, intermediate, and poor prognoses. The median survival times for these three groups were 410, 239, and 143 days, respectively (P < 0.01). CONCLUSIONS: The results may be helpful in predicting life expectancy, determining treatment strategies, and designing future clinical trials. Copyright 2001 American Cancer Society.
BACKGROUND: The combination of radiation therapy and chemotherapy (chemoradiotherapy [CRT]) has been accepted as standard therapy for patients with locally advanced pancreatic carcinoma (PC). This study investigated prognostic factors in patients with locally advanced PC receiving CRT. METHODS: Fifty-five consecutive patients with locally advanced PC, who received concurrent radiotherapy (50.4 grays) and chemotherapy using 5-fluorouracil or cisplatin, were analyzed retrospectively to investigate prognostic factors. RESULTS: Median survival time and overall survival rates at 1 and 2 years were 301 days, 35.1% and 2.4%, respectively. By multivariate analysis using the Cox proportional hazards model, performance status of 0-1 (P < 0.01), absence of regional lymph node swelling (P < 0.01), and serum CA 19-9 level of less than 1000 (P = 0.02) were independent favorable prognostic factors. A prognostic index based on the coefficients of those prognostic factors was used to classify patients into three groups with good, intermediate, and poor prognoses. The median survival times for these three groups were 410, 239, and 143 days, respectively (P < 0.01). CONCLUSIONS: The results may be helpful in predicting life expectancy, determining treatment strategies, and designing future clinical trials. Copyright 2001 American Cancer Society.
Authors: Sonali Rudra; Amol K Narang; Timothy M Pawlik; Hao Wang; Elizabeth M Jaffee; Lei Zheng; Dung T Le; David Cosgrove; Ralph H Hruban; Elliot K Fishman; Richard Tuli; Daniel A Laheru; Christopher L Wolfgang; Luis A Diaz; Joseph M Herman Journal: Pract Radiat Oncol Date: 2012
Authors: Thomas Zacharias; Elie Oussoultzoglou; Daniel Jaeck; Patrick Pessaux; Philippe Bachellier Journal: J Gastrointest Surg Date: 2008-12-03 Impact factor: 3.452
Authors: Bradley J Barney; Xin Shelley Wang; Charles Lu; Zhongxing Liao; Valen E Johnson; Charles S Cleeland; Tito R Mendoza Journal: Qual Life Res Date: 2013-01-31 Impact factor: 4.147
Authors: Clinton W Ali; Thomas F Kaye; Douglas J A Adamson; Iain S Tait; Francesco M Polignano; Martin S Highley Journal: J Gastrointest Cancer Date: 2007